Aglepristone, a competitive progesterone antagonist, is successfully used in various progesterone-dependent conditions. This study investigated uterine histomorphometric analysis, and expressions of the oestrogen α receptor (ERα) and progesterone receptor (PR) in uteri of bitches following the single dose of aglepristone treatment. Twelve client-owned healthy diestrous bitches were used in the study. The single dose of aglepristone (Alizine^®, 10 mg/kg) was injected subcutaneously 5 days before ovariohysterectomy in the treatment group (n = 6); bitches without treatment served as a control group (n = 6). Uteri were collected for histomorphometric analysis, ERα and PR gene, and protein expressions studies. The mRNA expressions of ERα and PR were determined by RT-qPCR. Immunohistochemical analysis was used to evaluate the ERα and PR protein expressions using an H-score in five parts of the uterus. The results demonstrated glandular epithelium height significantly decreased (p < .05) and ERα mRNA increased (p < .01) in treated dogs. Of the treated bitches, lower expression levels of ERα were observed in the luminal epithelium, crypt and glandular epithelium, with higher expression in the endometrial stroma and myometrium (p < .05); however, PR expression decreased in the luminal epithelium, crypt and glandular epithelium (p < .01). In conclusion, reduction of the uterine glandular epithelium and ERα mRNA upregulation together with changes in ERα and PR expressions were observed in the treated bitches. However, changes in uterine ERα and PR expressions in the treated bitches depended on tissue layers. The treatment had no effect on serum oestradiol and progesterone levels.

中文翻译：

---

阿格列酮治疗后犬雌激素α和孕激素受体的分子研究和组织形态学分析

Aglepristone 是一种竞争性黄体酮拮抗剂，已成功用于各种黄体酮依赖性病症。本研究调查了子宫组织形态计量学分析，以及雌激素 α 受体 (ERα) 和孕激素受体 (PR) 在母犬接受单剂量阿格司酮治疗后子宫内的表达。研究中使用了 12 只客户拥有的健康失血母犬。aglepristone的单次剂量（Alizine ^®，10毫克/千克）经皮下注射治疗组（在卵巢子宫切除术前5天Ñ  = 6）; 未经治疗的母犬作为对照组（n = 6）。收集子宫用于组织形态学分析、ERα 和 PR 基因以及蛋白质表达研究。通过RT-qPCR测定ERα和PR的mRNA表达。使用免疫组织化学分析在子宫的五个部分中使用 H 评分评估 ERα 和 PR 蛋白表达。结果表明 ，治疗犬的腺上皮高度显着降低（p  < .05），ERα mRNA 增加（p < .01）。在接受治疗的母犬中，ERα 在管腔上皮、隐窝和腺上皮中的表达水平较低，而在子宫内膜基质和子宫肌层中的表达水平较高 ( p  < .05)；然而，PR 在管腔上皮、隐窝和腺上皮中的表达降低（p < .01)。总之，在治疗后的母犬中观察到子宫腺上皮细胞减少和 ERα mRNA 上调以及 ERα 和 PR 表达的变化。然而，接受治疗的母犬子宫 ERα 和 PR 表达的变化取决于组织层。治疗对血清雌二醇和孕酮水平没有影响。